Robeco Institutional Asset Management B.V. Has $27.89 Million Holdings in Royalty Pharma PLC $RPRX

Robeco Institutional Asset Management B.V. lifted its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 23.5% during the 2nd quarter, Holdings Channel reports. The fund owned 774,160 shares of the biopharmaceutical company’s stock after acquiring an additional 147,112 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Royalty Pharma were worth $27,893,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. USA Financial Formulas acquired a new position in shares of Royalty Pharma in the 2nd quarter worth approximately $32,000. Louisbourg Investments Inc. acquired a new position in Royalty Pharma during the 1st quarter worth $28,000. Summit Securities Group LLC acquired a new position in Royalty Pharma during the 1st quarter worth $36,000. WPG Advisers LLC acquired a new position in Royalty Pharma during the 1st quarter worth $39,000. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in Royalty Pharma by 42.1% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,358 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 402 shares in the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on RPRX shares. Wall Street Zen downgraded Royalty Pharma from a “buy” rating to a “hold” rating in a report on Saturday, September 13th. Citigroup upped their price objective on Royalty Pharma from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, July 22nd. The Goldman Sachs Group started coverage on Royalty Pharma in a report on Tuesday. They set a “buy” rating and a $42.00 price objective on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Royalty Pharma in a report on Saturday, September 27th. Finally, Morgan Stanley upped their price objective on Royalty Pharma from $51.00 to $54.00 and gave the stock an “overweight” rating in a report on Thursday, July 10th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $46.00.

Royalty Pharma Stock Performance

Shares of Royalty Pharma stock opened at $36.07 on Friday. The company has a market capitalization of $21.03 billion, a PE ratio of 20.85, a PEG ratio of 2.28 and a beta of 0.60. Royalty Pharma PLC has a 12 month low of $24.05 and a 12 month high of $38.00. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 0.74. The stock’s fifty day simple moving average is $36.28 and its 200 day simple moving average is $34.55.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.04. The firm had revenue of $578.67 million during the quarter, compared to analysts’ expectations of $750.06 million. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%. On average, research analysts predict that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were issued a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Friday, August 15th. Royalty Pharma’s dividend payout ratio is 50.87%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.